Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study.
2018
e16167Background: PRRT, licensed for gastroenteropancreatic (GEP) NETs, has been used with somatostatin analogs such as lanreotide depot (LAN). PRELUDE is the first retrospective study to describe ...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI